Evaluating the feasibility of gene replacement strategies to treat MTRFR deficiency
Disease Models & Mechanisms · 2025
DOI: 10.1242/dmm.052120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2025. Verfasst von Samia L Pratt und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Jackson Laboratory, Bar Harbor, ME 04609, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Mitochondrial Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Muscular Dystrophy UK, LifeArc Centre to Treat Mitochondrial Diseases, National Ataxia Foundation.
Abstract (Originalsprache)
Mitochondrial translation release factor in rescue (MTRFR) catalyzes a termination step in protein synthesis, facilitating release of the nascent chain from mitoribosomes. Pathogenic variants in MTRFR cause MTRFR deficiency and are loss-of-function variants. Here, we tested gene replacement as a possible therapeutic strategy. A truncating mutation (K155*) was generated in mice; however, homozygotes die embryonically whereas mice heterozygous for this K155* allele are normal. We also generated transgenic strains expressing either wild-type human MTRFR or a partially functional MTRFR. Despite dose-dependent phenotypes from overexpression in vitro, neither transgene caused adverse effects in vivo. In K155* homozygous mice, the wild-type MTRFR transgene completely rescued the phenotype with only one copy present, whereas the mutant transgene rescued less efficiently. Detailed evaluation of mice rescued with the wild-type MTRFR transgene revealed no abnormalities. In human induced pluripotent stem cell (hiPSC)-derived knockdown neurons, mitochondrial phenotypes were corrected by AAV9-mediated delivery of MTRFR. Thus, we find no toxicity from truncated gene products or overexpression of MTRFR in vivo, and expression of MTRFR corrects phenotypes in both mouse and hiPSC models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Jackson Laboratory, Bar Harbor, ME 04609, USA.
- Neuroscience Ph.D. Program, Graduate School of Biomedical Science, Tufts University, Boston, MA 02111, USA.
- Department of Clinical Neurosciences, John Van Geest Centre for Brain Repair, University of Cambridge, CB2 0PY Cambridge, UK.
- Institute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.
- Drug Research Program, Faculty of Pharmacy, University of Helsinki, 00014 Helsinki, Finland.
ORCID-Profile: Robert W Burgess
Förderung
- Muscular Dystrophy UK
- LifeArc Centre to Treat Mitochondrial Diseases
- National Ataxia Foundation
- Action for A-T
- Helsingin Yliopisto
- NINDS NIH HHS
- Research Council of Finland
- Hereditary Disease Foundation
Zitieren
APA
Pratt, S. L., Zarate-Mendez, M., Koludarova, L., Jansson, S., Airavaara, M., Hlushchuk, I., Coleman, D., Heffner, C., Horvath, R., Battersby, B. J., & Burgess, R. W. (2025). Evaluating the feasibility of gene replacement strategies to treat MTRFR deficiency. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.052120
Vancouver
Pratt SL, Zarate-Mendez M, Koludarova L, Jansson S, Airavaara M, Hlushchuk I, et al. Evaluating the feasibility of gene replacement strategies to treat MTRFR deficiency. Disease Models & Mechanisms. 2025. doi:10.1242/dmm.052120
BibTeX
@article{Pratt2025,
author = {Pratt, Samia L and Zarate-Mendez, Mariana and Koludarova, Lidiia and Jansson, Sonja and Airavaara, Mikko and Hlushchuk, Irena and Coleman, David and Heffner, Caleb and Horvath, Rita and Battersby, Brendan J and Burgess, Robert W},
title = {Evaluating the feasibility of gene replacement strategies to treat MTRFR deficiency},
journal = {Disease Models & Mechanisms},
year = {2025},
doi = {10.1242/dmm.052120}
}
EUVIMED